AngioDynamics (ANGO) Downgrade of Rating
EU-listed Angiodynamics (ANGO), was decreased by stock research analysts at Craig-Hallum. Craig-Hallum decreased its rating on the $ market cap company to Hold from a previous Buy.
The firm’s rating downgrade was noticed by stock traders, as ANGO is right now trading 0.00% lower at $0.00 as of 12:11 AM New York time. AngioDynamics shares have [From2] 0% in the last 200 days, while the S&P 500 Index has gained 6.00% in the same time period.
According to data compiled by Thomson Reuters, AngioDynamics (ANGO)’s stock is covered by 4 equity analysts across the Street, with 0 analysts giving it a Sell rating, 3 a Buy rating, while 1 consider it a Hold. The 12-month consensus target price for the stock is $14.63, which reflects an upside potential of ∞% over the current price.
Rgm Capital Llc had the biggest stake with ownership of 2.70M shares as of Q2 2015 for 5.34% of the US long equity exposure. Broadfin Capital Llc is another very bullish fund who is possessing 2.89M shares of AngioDynamics or 4.54% of their US long equity exposure. Also, Lapides Asset Management Llc have 1.72% of their US long equity exposure invested in the company for 574,400 shares. The Minnesota-based fund Perkins Capital Management Inc revealed it had purchased a stake worth about 0.91% of the fund’s stock portfolio in AngioDynamics. The Pennsylvania-based fund Tfs Capital Llc is also positive about the stock, possessing 51,850 shares or 0.49% of their US long equity exposure.
AngioDynamics (ANGO) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. AngioDynamics has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest AngioDynamics (ANGO) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post AngioDynamics (ANGO) Rating Cut by Analysts at Craig-Hallum to Hold appeared first on Octafinance.